Therefore, our amino acid-based PROTACs may not only be effective for PD by targeting α-syn degradation but could also be adapted toward other neurodegenerative diseases, including AD by targeting tau and Aβ degradation, and ALS by targeting TDP-43 degradation. This evidence concerns the gene MAPT and Parkinson disease.